Monitor for actual Form 4 filings to confirm whether the sale was executed. The officer's option exercise and immediate sale intent suggest a desire to lock in gains or raise cash, which may weigh on sentiment. Given the stock's recent resilience to bearish signals, the impact may be muted unless followed by additional insider sales.
Price Chart
Executive Summary
Eric Karas, an officer of ARS Pharmaceuticals, filed a Form 144 notice of intent to sell 100,000 shares of common stock, with an approximate market value of $410,240 as of the filing date. The shares are being sold following a stock option exercise, and the filing signals insider intent to monetize equity ahead of any potential near-term catalyst.
Key Facts
- Insider Eric Karas (Officer) filed Form 144 to sell 100,000 shares of common stock.
- Estimated aggregate market value of the proposed sale is $410,240.
- Shares are to be sold through Morgan Stanley Smith Barney LLC.
- The sale follows a stock option exercise on 10/19/2026.
- The filing was made on 10/19/2026, with the proposed sale date also 10/19/2026.
- The company's outstanding shares are approximately 99,447,343, making the sale ~0.1% of total shares outstanding.
Financial Impact
Proposed sale of 100,000 shares valued at approximately $410,240, representing ~0.1% of total shares outstanding.
Risk Factors
- Form 144 is an intent to sell; the sale may not occur, reducing the signal's reliability.
- Historical bearish calls on SPRY have been incorrect (stock rallied), so the market may not react negatively to this insider sale.
- The sale represents a small fraction of total shares outstanding, limiting direct price impact.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-010301 |
| Document: 0001950047-26-010301-index.html | 0001950047-26-010301 |
| Document: 0001950047-26-010301.txt | 0001950047-26-010301 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 6d ago | 144 | $4.29 $4.18 | ▲ +2.56% | ▲ +3.09% | $4.03 (+6.06%) |
Sep 28, 2026 28d ago | Court Ruling | $4.40 $4.31 | ▼ −2.05% | ▼ −1.84% | $4.03 (−8.41%) |
Sep 16, 2026 5w ago | Court Ruling | $4.15 $4.11 | ▼ −0.96% | ▼ −0.84% | $4.03 (−2.89%) |
Aug 3, 2026 12w ago | Press Release | $5.46 $5.32 | ▼ −2.56% | ▼ −4.37% | $4.03 (−26.19%) |
Jul 17, 2026 14w ago | Court Ruling | $6.44 $6.36 | ▼ −1.24% | ▼ −2.08% | $4.03 (−37.42%) |
Jul 7, 2026 15w ago | 8-K | $8.10 $7.88 | ▼ −2.72% | ▼ −3.56% | $4.03 (−50.25%) |
Jun 12, 2026 19w ago | Insider Cluster | $9.81 $9.70 | ▼ −1.12% | ▼ −0.53% | $4.03 (−58.92%) |
May 15, 2026 23w ago | 8-K | $7.43 $7.30 | ▼ −1.68% | ▼ −1.62% | $4.03 (−45.72%) |
May 15, 2026 23w ago | Press Release | $7.43 $7.30 | ▲ +1.68% | ▲ +1.62% | $4.03 (+45.72%) |
May 13, 2026 23w ago | 8-K | $8.01 $7.94 | ▼ −0.87% | ▼ −1.65% | $4.03 (−49.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers